Logos Capital is a fundamental biotechnology-focused investment fund.
Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifying compelling investment ideas and uncorrelated-market returns. They combine scientific diligence with their statistical modeling of clinical trials to achieve the highest levels of conviction in each position.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 6, 2022
Entact Bio
|
Series A | $81M | Biopharma | — |
Dec 7, 2021
Freenome
|
Series D | $300M | Biotechnology | — |
Oct 7, 2021
Neumora Therapeutics
|
Series A | $400M | Biotechnology | — |
Jul 13, 2021
Nimbus Therapeutics
|
Series Unknown | $105M | Biotechnology | — |
Jun 29, 2021
Element Biosciences
|
Series C | $276M | Biotechnology | — |